Program Content


  • FAQs on ICIs in NSCLC
    Expert Answers to FAQs on Immune Checkpoint Inhibitors for NSCLC
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 26, 2022

    Expires: August 25, 2023

    View Activity


cover img faculity

Julie Brahmer, MD

Associate Professor of Oncology
Oncology/Upper Aerodigestive Cancer Program
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

cover img faculity

Natasha Leighl, MD, MMSC, FRCPC, FASCO

Natasha Leighl, MD, FRCPC, FASCO,
Lung Site Lead, Medical Oncology
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine, University of Toronto
Toronto, Canada

cover img faculity

Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Professor of Oncology
Sidney Kimmel Comprehensive
Johns Hopkins University
Baltimore, Maryland

Provided by

ProCE Banner



Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme